Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of $0.18, $0.12 better than the analyst estimate of $0.06. Revenue for the quarter came in at $307.96 million versus the consensus estimate of $296.02 million.

FY 2026 Outlook:-

Revenue between $1.24 to $1.30 billion vs consensus $1.24 billion.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.